Clinical Trial Update: Patient Tolerability Study of GSK163090 [Phase 1]

View source ↗

Summary

GlaxoSmithKline completed a Phase 1 tolerability study of the investigational compound GSK163090 in adults with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• GSK163090

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD) | Phase 1 | Status: COMPLETED